Bempedoic acid: a new player for statin-intolerant patients and beyond

被引:2
作者
Giordano, Salvatore [1 ]
Spaccarotella, Carmen Anna Maria [2 ]
Esposito, Giovanni [2 ]
Indolfi, Ciro [1 ,3 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Div Cardiol, Catanzaro, Italy
[2] Univ Naples Federico II, Dept Adv Biomed Sci, Div Cardiol, Naples, Italy
[3] Magna Graecia Univ Catanzaro, Univ Catanzaro, I-88100 Catanzaro, Italy
关键词
bempedoic acid; cardiovascular outcomes; hypercholesterolemia; low-density lipoprotein cholesterol; statin-intolerance; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; LDL CHOLESTEROL; HIGH-RISK; SAFETY; EFFICACY;
D O I
10.1097/MED.0000000000000853
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of reviewLow-density lipoproteins (LDL) cause atherosclerotic cardiovascular disease, a condition associated with significant morbidity and mortality. Statins represent the cornerstone for preventing cardiovascular events in patients with elevated LDL-cholesterol (LDL-C) levels, however, they are associated with frequent musculoskeletal adverse effects, which lead to drug discontinuation or limit their use to low (and less effective) doses. Bempedoic acid (BA) is a newly approved, safe, cholesterol-lowering agent that inhibits ATP-citrate lyase, an enzyme upstream to 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the target of statins. Unlike statins, BA is not associated with musculoskeletal side effects, representing a promising drug for statin-intolerant patients. This review aims to summarize the current evidence on the efficacy, safety, and impact on clinical outcomes of BA, to review current indications for its use, and to highlight the ongoing clinical trials that will help deepen our knowledge of this promising compound.Recent findingsBA improves clinical outcomes in statin-intolerant patients. Multiple ongoing studies are evaluating whether BA can be employed in other clinical settings.SummaryBA safely and effectively reduces the levels of multiple atherogenic markers and can be employed to reach LDL-C targets independently from statin tolerance.
引用
收藏
页码:90 / 97
页数:8
相关论文
共 20 条
  • [11] Bempedoic Acid for High-Risk Primary Prevention of Cardiovascular Disease Not a Statin Substitute but a Good Plan B
    Kazi, Dhruv S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (02): : 123 - 125
  • [12] Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
    Leiter, Lawrence A.
    Banach, Maciej
    Catapano, Alberico L.
    Duell, P. Barton
    Gotto, Antonio M., Jr.
    Laufs, Ulrich
    Mancini, G. B. John
    Ray, Kausik K.
    Hanselman, Jeffrey C.
    Ye, Zhan
    Bays, Harold E.
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (05) : 868 - 880
  • [13] Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]
  • [14] Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
    Nissen, S. E. E.
    Lincoff, A. M.
    Brennan, D.
    Ray, K. K. K.
    Mason, D.
    Kastelein, J. J. P.
    Thompson, P. D. D.
    Libby, P.
    Cho, L.
    Plutzky, J.
    Bays, H. E. E.
    Moriarty, P. M. M.
    Menon, V
    Grobbee, D. E. E.
    Louie, M. J. J.
    Chen, C-F
    Li, N.
    Bloedon, L. A.
    Robinson, P.
    Horner, M.
    Sasiela, W. J. J.
    McCluskey, J.
    Davey, D.
    Fajardo-Campos, P.
    Petrovic, P.
    Fedacko, J.
    Zmuda, W.
    Lukyanov, Y.
    Nicholls, S. J. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (15) : 1353 - 1364
  • [15] Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
    Nissen, Steven E.
    Menon, Venu
    Nicholls, Stephen J.
    Brennan, Danielle
    Laffin, Luke
    Ridker, Paul
    Ray, Kausik K.
    Mason, Denise
    Kastelein, John J. P.
    Cho, Leslie
    Libby, Peter
    Li, Na
    Foody, JoAnne
    Louie, Michael J.
    Lincoff, A. Michael
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (02): : 131 - 140
  • [16] Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
    Pinkosky, Stephen L.
    Newton, Roger S.
    Day, Emily A.
    Ford, Rebecca J.
    Lhotak, Sarka
    Austin, Richard C.
    Birch, Carolyn M.
    Smith, Brennan K.
    Filippov, Sergey
    Groot, Pieter H. E.
    Steinberg, Gregory R.
    Lalwani, Narendra D.
    [J]. NATURE COMMUNICATIONS, 2016, 7
  • [17] EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
    Ray, Kausik K.
    Molemans, Bart
    Schoonen, W. Marieke
    Giovas, Periklis
    Bray, Sarah
    Kiru, Gaia
    Murphy, Jennifer
    Banach, Maciej
    De Servi, Stefano
    Gaita, Dan
    Gouni-Berthold, Ioanna
    Hovingh, G. Kees
    Jozwiak, Jacek J.
    Jukema, J. Wouter
    Kiss, Robert Gabor
    Kownator, Serge
    Iversen, Helle K.
    Maher, Vincent
    Masana, Luis
    Parkhomenko, Alexander
    Peeters, Andre
    Clifford, Piers
    Raslova, Katarina
    Siostrzonek, Peter
    Romeo, Stefano
    Tousoulis, Dimitrios
    Vlachopoulos, Charalambos
    Vrablik, Michal
    Catapano, Alberico L.
    Poulter, Neil R.
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (11) : 1279 - 1289
  • [18] Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
    Ray, Kausik K.
    Bays, Harold E.
    Catapano, Alberico L.
    Lalwani, Narendra D.
    Bloedon, LeAnne T.
    Sterling, Lulu R.
    Robinson, Paula L.
    Ballantyne, Christie M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (11) : 1022 - 1032
  • [19] Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial
    Rubino, John
    MacDougall, Diane E.
    Sterling, Lulu Ren
    Kelly, Stephanie E.
    McKenney, James M.
    Lalwani, Narendra D.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2021, 15 (04) : 593 - 601
  • [20] Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial
    Rubino, John
    MacDougall, Diane E.
    Sterling, Lulu R.
    Hanselman, Jeffrey C.
    Nicholls, Stephen J.
    [J]. ATHEROSCLEROSIS, 2021, 320 : 122 - 128